Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

查看全文 作　　者：Feng [1]Tang;Zhiyong [1]Pan;Yi [2]Wang;Tian [1]Lan;Mengyue [2]Wang;Fengping [1]Li;Wei [1]Quan;Zhenyuan [1]Liu;Zefen [2]Wang;Zhiqiang [1]Li

机构地区：[1]Brain Glioma Center and Department of Neurosurgery,Wuhan University Zhongnan Hospital,Wuhan,430071,China;[2]Department of Physiology,Wuhan University School of Basic Medical Sciences,Wuhan,430071,China

出　　处：《Neuroscience Bulletin》索引2022年第38卷第9期,共16页

基　　金：supported by the Translational Medicine Research Fund of Zhongnan Hospital of Wuhan University(ZLYNXM202011 and ZNLH201901);the National Health Commission of China(2018ZX-07S-011). 摘　　要：Isocitrate dehydrogenase(IDH)is an essential metabolic enzyme in the tricarboxylic acid cycle(TAC).The high mutation frequency of the IDH gene plays a complicated role in gliomas.In addition to affecting gliomas directly,mutations in IDH can also alter their immune microenvironment and can change immune-cell function in direct and indirect ways.IDH mutations mediate immune-cell infiltration and function by modulating immune-checkpoint gene expression and chemokine secretion.In addition,IDH mutation-derived D2-hydroxyglutarate can be absorbed by surrounding immune cells,also affecting their functioning.In this review,we summarize current knowledge about the effects of IDH mutations as well as other gene mutations on the immune microenvironment of gliomas.We also describe recent preclinical and clinical data related to IDH-mutant inhibitors for the treatment of gliomas.Finally,we discuss different types of immunotherapy and the immunotherapeutic potential of IDH mutations in gliomas. 关键词：IDH mutation Tumor immune microenvironment IMMUNOTHERAPY GLIOMA

相关文献

参考文献（145）
引证文献（1）
耦合文献（154）

参考文献(145)

引证文献(1)

耦合文献(154)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

参考文献(145)

引证文献(1)

耦合文献(154)

用户提示